Gastrointestinal Diseases
Show Only Open Trials
1.
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg- Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C (AI444-052)
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Treatment-Naive Chronic Hepatitis C
2.
Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B
- Study Status: Open to Enrollment
- Sponsor: Gilead Sciences, Inc.
- Disease Status and/or Stage: Chronic Hepatitis B
3.
Phase II Trial of TMC435 in Combination With PSI-7977 in Prior G1 Null Responders to Peg-IFN/RBV, Hepatitis C-Infected Patients
- Study Status: Open to Enrollment
- Sponsor: Tibotec Pharmaceuticals
- Disease Status and/or Stage: Hepatitis C
4.
A Phase 2a, Pilot, Open-Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624 in Subjects With Fibrosis of the Liver
- Study Status: Open to Enrollment
- Sponsor: Gilead Sciences
- Disease Status and/or Stage: Chronic Liver Disease and Liver Fibrosis of Any Cause
5.
REO 022: A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients with Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
- Study Status: Open to Enrollment
- Sponsor: Oncolytics Biotech, Inc.
- Disease Status and/or Stage: Colon Cancer
6.
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)
7.
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
- Study Status: Closed to Enrollment
- Sponsor: New York Cancer Consortium
- Disease Status and/or Stage: Gastric or Gastroesophageal Junction (GEJ) Cancer Not Amenable to Surgical Resection
8.
A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer
9.
A Randomized, Double-Blind, Phase 1b Study to Assess the Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Treatment-Naive HCV Mono-Infected Adults
- Study Status: Open to Enrollment
- Sponsor: NIAID
- Disease Status and/or Stage: Treatment Naive Hepatitis C
10.
A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors
- Study Status: Closed to Enrollment
- Sponsor: BiPar Sciences
- Disease Status and/or Stage: Metastatic Pancreatic Cancer
11.
A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.
- Study Status: Closed to Enrollment
- Sponsor: Immunomedics, Inc.
- Disease Status and/or Stage: Untreated Advanced Pancreatic Cancer
12.
Once-Daily Oral E5501 Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
- Study Status: Closed to Enrollment
- Sponsor: Eisai Inc.
- Disease Status and/or Stage: Chronic Liver Disease
13.
A MULTI-CENTER, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICSOF PSI-7977 IN COMBINATION WITH PEGYLATED INTERFERON AND RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV INFECTION
- Study Status: Closed to Enrollment
- Sponsor: Pharmasset
- Disease Status and/or Stage: Chronic Hepatitis C
14.
A 3-Year, Virology Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
- Study Status: Closed to Enrollment
- Sponsor: Vertex
15.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-9190, GS-9256, Ribavirin (Copegus®), and Peginterferon Alfa 2a (Pegasys®) in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Infection
- Study Status: Closed to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Chronic Hepatitis C
16.
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
- Study Status: Closed to Enrollment
- Sponsor: Roche
- Disease Status and/or Stage: Chronic Hepatits C
17.
A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response in patients treated with DAA-containing regimens for chronic hepatitis C infection
- Study Status: Open to Enrollment
- Sponsor: Roche
- Disease Status and/or Stage: Chronic Hepatitis C
18.
Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial for the Treatment of Chronic Hepatitis C in which SCH 503034 was Administered (P05063)
- Study Status: Open to Enrollment
- Sponsor: Schering Plough Research Institute
